In a CKD patient with eGFR 27 mL/min/1.73 m² and proteinuria ~1 g/day who is tolerating perindopril without hyperkalaemia, is switching to telmisartan 20 mg appropriate?

Switching from Perindopril to Telmisartan 20 mg in Advanced CKD

Switching from perindopril to telmisartan 20 mg is inappropriate and potentially harmful in this patient with eGFR 27 mL/min/1.73 m² and proteinuria ~1 g/day who is tolerating perindopril without hyperkalemia. The patient should continue perindopril and titrate to the highest tolerated dose rather than switching to a subtherapeutic dose of an ARB. 1

Why This Switch Is Not Recommended

Continue Current ACE Inhibitor Therapy

• KDIGO 2024 guidelines explicitly state that ACE inhibitors or ARBs should be continued even when eGFR falls below 30 mL/min/1.73 m², with consideration for discontinuation only when eGFR drops below 15 mL/min/1.73 m² or when symptomatic hypotension or uncontrolled hyperkalemia develop. 1, 2
• This patient has eGFR 27 mL/min/1.73 m² (CKD stage G4) with proteinuria ~1 g/day and is tolerating perindopril without hyperkalemia—there is no indication to stop or switch the current therapy. 1
• The perindopril FDA label confirms safety in patients with creatinine clearance >30 mL/min, stating that initial dosing should be 2 mg/day with maximum 8 mg/day in this population. 3

Problems with Telmisartan 20 mg Specifically

The proposed dose of telmisartan 20 mg is subtherapeutic and will not provide adequate renoprotection. 2

• KDIGO guidelines emphasize titrating to the highest approved dose of ACE inhibitors or ARBs that is tolerated, because clinical trials demonstrated that renoprotective and cardiovascular benefits are achieved at target doses rather than lower maintenance doses. 1, 2
• Telmisartan 20 mg is the lowest available dose and is inadequate for a patient with significant proteinuria (1 g/day) who requires maximal RAS blockade. 2
• Studies demonstrating renoprotective effects of telmisartan in advanced CKD used doses of 40-80 mg daily, not 20 mg. 4, 5

Avoid Dual RAS Blockade

Never combine an ACE inhibitor with an ARB, as this dual RAS blockade increases the risk of hyperkalemia, hypotension, and acute kidney injury without providing additional clinical benefit. 1, 2

• If the provider is considering adding telmisartan to perindopril, this combination is explicitly contraindicated by KDIGO guidelines. 1, 2
• The ONTARGET trial demonstrated that combination ACE inhibitor plus ARB therapy worsened major renal outcomes compared to monotherapy, with increased dialysis or doubling of serum creatinine (HR 1.24, p=0.038). 6

Correct Management Strategy

Optimize Current Perindopril Therapy

The appropriate action is to titrate perindopril upward toward the target dose of 8 mg daily (the maximum recommended dose in patients with eGFR >30 mL/min/1.73 m²). 1, 3

• Begin with low-dose ACE inhibitors in patients with moderate CKD (eGFR 30-60 mL/min/1.73 m²), then titrate gradually toward guideline-recommended target doses. 1
• The perindopril FDA label specifies that for patients with creatinine clearance >30 mL/min, the initial dose should be 2-4 mg daily with titration up to 8 mg daily as tolerated. 3

Monitoring Protocol After Dose Adjustment

Check serum creatinine and potassium 2-4 weeks after any dose increase of perindopril. 1, 2

• Continue ACE inhibitor therapy unless serum creatinine rises by more than 30% within 4 weeks of dose escalation; a rise up to 30% reflects the intended hemodynamic effect (reduced intraglomerular pressure) and is associated with long-term renoprotection. 1
• Manage hyperkalemia with potassium-lowering strategies (dietary restriction, diuretic optimization, sodium bicarbonate, gastrointestinal cation exchangers) rather than immediate ACE inhibitor cessation. 1

Add Complementary Renoprotective Therapies

Consider adding an SGLT2 inhibitor if not already prescribed, as KDIGO gives a strong recommendation for SGLT2 inhibitors in patients with eGFR ≥20 mL/min/1.73 m² and urine albumin-to-creatinine ratio ≥200 mg/g (approximately 1 g/day proteinuria). 2

• SGLT2 inhibitors provide additive renoprotection when combined with ACE inhibitors or ARBs without increasing hyperkalemia risk. 2

Common Pitfalls to Avoid

Do Not Switch Based on Class Preference Alone

• There is no evidence that ARBs are superior to ACE inhibitors in advanced CKD; both classes provide equivalent renoprotection when used at target doses. 1, 7
• Switching from a well-tolerated ACE inhibitor to an ARB at a subtherapeutic dose abandons proven benefit without justification. 1

Do Not Discontinue RAS Inhibition Prematurely

• The benefits of ACE inhibitors in slowing CKD progression outweigh risks even in advanced CKD (eGFR <30 mL/min/1.73 m²). 1, 2
• Discontinuation should only occur at eGFR <15 mL/min/1.73 m² and when symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms develop. 1, 2

Recognize Therapeutic Creatinine Elevations

• An increase in serum creatinine up to 30% after ACE inhibitor initiation or dose escalation should be recognized as a therapeutic hemodynamic effect, not acute kidney injury. 1
• This hemodynamic response indicates effective reduction of intraglomerular pressure and predicts long-term renoprotection. 1